What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications?
Listen now
Description
Drs John Kane and Christoph U. Correll discuss the major metabolic and neurologic risks associated with antipsychotic medications for patients diagnosed with schizophrenia. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969525). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Schizophrenia https://www.medscape.com/resource/schizophrenia Understanding the Effects of Antipsychotics on Appetite Control https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762106/ Food and Drug Administration's Obesity Drug Guidance Document https://www.ahajournals.org/doi/10.1161/circulationaha.111.028381 Risk of Weight Gain for Specific Antipsychotic Drugs: A Meta-analysis https://www.nature.com/articles/s41537-018-0053-9 Diabetes and Schizophrenia https://link.springer.com/article/10.1007/s11892-015-0704-4 Brain Insulin Action: Implications for the Treatment of Schizophrenia https://www.sciencedirect.com/science/article/abs/pii/S0028390819301960?via%3Dihub Obesity as a Risk Factor for Accelerated Brain Ageing in First-Episode Psychosis -- A Longitudinal Study https://academic.oup.com/schizophreniabulletin/article-abstract/47/6/1772/6291438 Body Mass Index Identified as an Independent Predictor of Psychiatric Readmission https://pubmed.ncbi.nlm.nih.gov/25004198/#:~:text=Conclusions%3A%20Body%20mass%20index%20was,be%20explored%20in%20prospective%20studies Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort https://pubmed.ncbi.nlm.nih.gov/30257079/ Incidence and Severity of Tardive Dyskinesia Increase With Age https://jamanetwork.com/journals/jamapsychiatry/article-abstract/492775 Extrapyramidal Symptoms With Atypical Antipsychotics: Incidence, Prevention and Management https://reference.medscape.com/medline/abstract/15733025
More Episodes
Drs John M. Kane and Mitchell Arnovitz discuss assessment of patients for negative symptoms of schizophrenia and the potential of MDMA in alleviating these symptoms in supervised treatment settings. Relevant disclosures can be found with the episode show notes on Medscape...
Published 07/20/23
Drs John M. Kane and Delbert G. Robinson discuss psychoeducation, treatment options, and possible side effects of medication for patients experiencing their first episode of schizophrenia. Relevant disclosures can be found with the episode show notes on Medscape...
Published 06/21/23